Results 161 to 170 of about 29,631 (205)

Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trials. [PDF]

Commun Med (Lond)
Hamada S, Suda M, Ishida K, Furihata K, Sogawa Y, Kumazaki M, Takahashi K, Sakakibara S, Matsunaga S, Jonai N, Nakayama T, Takeshita F.   +11 more
europepmc   +1 more source

Building better antibody responses: The interplay of infection, vaccination, and immune imprinting. [PDF]

PNAS Nexus
Carissa Aurelia L, Selva KJ, Chung AW.
europepmc   +1 more source

Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trial. [PDF]

NPJ Vaccines
Levine KS, Blanc R, Wang Q, Malca H, Sekulovich R, Jin H, Liu S, Verhoeven C, Sullivan B, Smolenov I, McNamara RP.   +10 more
europepmc   +1 more source

mRNA-based SARS-CoV-2 vaccines: intracellular processing and aggregation of the encoded spike protein as a mechanistic contributor to cardiac cellular stress. [PDF]

Front Immunol
Schreckenberg R, Woitasky N, Itani N, Czech L, Windhorst AC, Juchem M, Bär C, Thum T, Ferdinandy P, Schulz R.   +9 more
europepmc   +1 more source

Vaccine effectiveness across the Omicron evolutionary spectrum (BA.2, BA.5, XBB, JN.1, KP.3): a systematic review of studies published 2022-2025. [PDF]

BMC Infect Dis
Alhumaid S, Alkhars O, Algrafi AS, Dossary NA, Elhaj N, Majzoub RA, Turkistani JA, Alhumaid SM, Shaikh HAA, Aldiaram A, Alahmed AH, Alomran SA, AlQatifi MB, Alkolib MJ, Almubarak MS, Al-Helal H, Alhaddad AJ, Alsouaib HA, Albahrani AA, Aldera AH, Alnasser FM, Alhmeed N, Alsulaiman MS, Al Alawi Z, Alghazal HA.   +24 more
europepmc   +1 more source

Host Immune Responses to SARS-CoV-2 Vaccination in Northern Mexico: Structural Biology Insights and the Impact of Obesity. [PDF]

Int J Mol Sci
Medina-Ramírez CF, Chavelas-Reyes JL, Rodríguez-González JG, Fernández-Santos NA, Wei L, Cabrera-Santos FJ, Fuentes-Chávez EJ, Rodríguez-Martínez LM, Rodríguez Pérez MA.   +8 more
europepmc   +1 more source

A visual framework for classifying adaptive design clinical trials using the GATE frame and PICO terminology. [PDF]

Dialogues Health
Lora D, Lalueza Blanco A, Maestro de la Calle G, García Reyne A, Ruíz-Ruigómez M, Calderón EJ, Menéndez-Orenga M.   +6 more
europepmc   +1 more source

Immune Response to COVID-19 Vaccines: Updates in a Fast-Moving Scenario. [PDF]

Vaccines (Basel)
De Marco F.
europepmc   +1 more source

Comparison of Immune Responses and Safety Profiles Following a Fourth Heterologous Dose (Second Booster) with mRNA-1273 in Individuals Previously Vaccinated with Two Doses of CoronaVac and a Booster Dose of Either AZD1222 or BNT162b2. [PDF]

Vaccines (Basel)
Tangsathapornpong A, Nanthapisal S, Fukpho W, Bunjoungmanee P, Neamkul Y, Pontan K, Boonyarangkul A, Wanpen S, Thongphubeth K, Tharabenjasin P, Jaru-Ampornpan P.   +10 more
europepmc   +1 more source

Correction: Post-vaccination SARS-CoV-2 infections and antibody responses after BNT162b2 in patients with severe obesity: a retrospective cohort study. [PDF]

Front Endocrinol (Lausanne)
Kara Z, Ak T, Demir AN, Akçin R, Dinç HÖ, Taşkın HE, Gareayaghi N, Kocazeybek B, Yumuk VD.   +8 more
europepmc   +1 more source